227 related articles for article (PubMed ID: 23616122)
1. Progesterone/RANKL is a major regulatory axis in the human breast.
Tanos T; Sflomos G; Echeverria PC; Ayyanan A; Gutierrez M; Delaloye JF; Raffoul W; Fiche M; Dougall W; Schneider P; Yalcin-Ozuysal O; Brisken C
Sci Transl Med; 2013 Apr; 5(182):182ra55. PubMed ID: 23616122
[TBL] [Abstract][Full Text] [Related]
2. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase.
Hu H; Wang J; Gupta A; Shidfar A; Branstetter D; Lee O; Ivancic D; Sullivan M; Chatterton RT; Dougall WC; Khan SA
Breast Cancer Res Treat; 2014 Aug; 146(3):515-23. PubMed ID: 25007964
[TBL] [Abstract][Full Text] [Related]
3. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
4. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
5. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression.
Mukherjee A; Soyal SM; Li J; Ying Y; He B; DeMayo FJ; Lydon JP
FASEB J; 2010 Nov; 24(11):4408-19. PubMed ID: 20605949
[TBL] [Abstract][Full Text] [Related]
6. The biology of progesterone receptor in the normal mammary gland and in breast cancer.
Obr AE; Edwards DP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):4-17. PubMed ID: 22193050
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells.
Obr AE; Grimm SL; Bishop KA; Pike JW; Lydon JP; Edwards DP
Mol Endocrinol; 2013 Nov; 27(11):1808-24. PubMed ID: 24014651
[TBL] [Abstract][Full Text] [Related]
8. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.
Beleut M; Rajaram RD; Caikovski M; Ayyanan A; Germano D; Choi Y; Schneider P; Brisken C
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2989-94. PubMed ID: 20133621
[TBL] [Abstract][Full Text] [Related]
10. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
Schramek D; Sigl V; Penninger JM
Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
12. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells.
Lee HJ; Gallego-Ortega D; Ledger A; Schramek D; Joshi P; Szwarc MM; Cho C; Lydon JP; Khokha R; Penninger JM; Ormandy CJ
Development; 2013 Apr; 140(7):1397-401. PubMed ID: 23462470
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
14. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
15. New Selective Progesterone Receptor Modulators and Their Impact on the RANK/RANKL Complex Activity.
Błaszczak-Świątkiewicz K
Molecules; 2020 Mar; 25(6):. PubMed ID: 32183159
[TBL] [Abstract][Full Text] [Related]
16. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
17. 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer.
Brisken C; Scabia V
J Mol Endocrinol; 2020 Jul; 65(1):T81-T94. PubMed ID: 32508307
[TBL] [Abstract][Full Text] [Related]
18. Comment on "Progesterone/RANKL is a major regulatory axis in the human breast".
Wang J; Gupta A; Hu H; Chatterton RT; Clevenger CV; Khan SA
Sci Transl Med; 2013 Dec; 5(215):215le4. PubMed ID: 24337478
[TBL] [Abstract][Full Text] [Related]
19. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse.
Fernandez-Valdivia R; Mukherjee A; Ying Y; Li J; Paquet M; DeMayo FJ; Lydon JP
Dev Biol; 2009 Apr; 328(1):127-39. PubMed ID: 19298785
[TBL] [Abstract][Full Text] [Related]
20. From the ranks of mammary progesterone mediators, RANKL takes the spotlight.
Fernandez-Valdivia R; Lydon JP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):91-100. PubMed ID: 21964466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
